Welcome to our dedicated page for Hoth Therapeutics SEC filings (Ticker: HOTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hoth Therapeutics, Inc. (HOTH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company, Hoth uses forms such as 10-K, 10-Q, 8-K, and registration statements to report on its business, financial condition, and material events.
In its Form 8-K filings, Hoth has reported items such as corporate presentations, employment agreements with key executives, patent-related developments for HT-001, and listing-compliance matters with The Nasdaq Capital Market. These current reports can give investors insight into topics like executive compensation arrangements, intellectual property strategy, and communications the company uses in discussions with investors.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically include detailed descriptions of Hoth’s pipeline programs, risk factors, research and development expenses, and other information relevant to its operations as a clinical-stage biopharmaceutical company. For Hoth, this may encompass narrative and disclosures related to HT-001, HT-KIT, HT-ALZ, its GDNF-based metabolic program, and other assets described in its public communications.
Stock Titan enhances access to these filings with AI-powered summaries that are designed to highlight key points from lengthy documents, such as major pipeline updates, regulatory milestones, or changes in capital structure. Users can review real-time updates as new filings are posted to EDGAR, explore Form 4 insider transaction reports when filed, and quickly navigate to sections that discuss clinical development, intellectual property, and corporate governance.
By using this page, investors and researchers can examine HOTH’s SEC filings alongside AI-generated explanations that aim to clarify complex language and help identify significant disclosures without replacing the need to read the original documents.
Hoth Therapeutics, Inc. ("HOTH") reported that, on June 18, 2025, The Nasdaq Stock Market notified the company that its common stock satisfied the minimum bid price requirement of $1.00 per share for at least ten consecutive business days, thereby restoring full compliance with Nasdaq Listing Rule 5550(a)(2). The company disclosed the notification in this Form 8-K and simultaneously issued a press release, furnished as Exhibit 99.1.